Aneuploid cancer cells were seeded in 96-well plates and treated with control siRNA oligos or oligos specific to BRCA1 or p19arf. mRNA levels of (a) BRCA1 and (b) p19arf were determined by quantitative real-time PCR. BRCA1 or p19arf mRNA levels were normalized to ACTB. To calculate the knockdown efficiency, the normalized BRCA1 or p19arf mRNA levels in the cells treated with BRCA1 or p19arf siRNA were compared to the control, which was arbitrarily set as 100. Supplementary Figure S12 . Analysis of apoptotic cells in adenoma and adenocarcinoma by the TUNEL assays. Tumor cells were isolated from adenoma (a poll of eight small tumors with diameters of 1-2 mm) or adenocarcinoma (a pool of three large tumors with diameters of 3-5 mm). Cells isolated from the normal lungs (12 m) were used as a negative control. Cells were labeled with FITC-dUTP and PI using the APO-DIRECT kit (BD Pharmingen) following the manufacture's instruction. Based on the staining of normal lung cells, which are predominantly non-apoptotic cells, those with FITC intensities that were greater than 500 were considered as apoptotic cells. Dotted line: Cutoff for quantification of apoptotic cells. Recombinant c-myc-tagged p14arf, which was purified using the affinity purification kit, was resolved on the 4-15% SDS-PAGE, followed by Coomassie blue staining (left) or and Western blotting analysis (right) using an antibody against the human p14arf (Santa Cruz Biotechnologies). Figure 7A . 2 Pool of eight small lung tumors.
